Novartis: announces tislelizumab study results

(CercleFinance.com) - Novartis has announced that tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in a Phase III study.


The group intends to submit these data to regulatory authorities and will work with BeiGene to present them at an upcoming medical meeting.

People with esophageal cancer face painful daily challenges and generally have a poor prognosis, with a five-year survival rate of about 5% for metastatic cases, underscoring the urgency of having more immunotherapy options, medical sources said.


Copyright (c) 2022 CercleFinance.com. All rights reserved.